Guggenheim Securities Expands Healthcare Investment Banking & Advisory Practice

    Guggenheim Securities Expands Healthcare Investment Banking & Advisory

Appointments Represent Commitment to Strengthening a Cornerstone of the Firm's
Investment Banking Platform

PR Newswire

NEW YORK, Aug. 8, 2012

NEW YORK, Aug. 8, 2012 /PRNewswire/ -- Guggenheim Partners, LLC
("Guggenheim"), a global diversified financial services firm, today announced
the appointments of Stuart Duty, Ron Gerber and Barry Shin to Guggenheim
Securities' healthcare investment banking and advisory team.

Based in New York, Messrs. Duty, Gerber and Shin join an existing team led by
Alan Schwartz, Executive Chairman of Guggenheim Partners, and Ken Springer,
Senior Managing Director.

"Stuart, Ron and Barry will add significant expertise to our growing
healthcare platform," said Mr. Schwartz. "This sector is core to our
investment banking business, and their deep industry relationships and
experience, especially in equity new issuance and life sciences M&A, will be
invaluable as we continue to expand our franchise."

With over 20 years of experience in the life sciences sector, Mr. Duty joins
as a Senior Managing Director with responsibility for helping build the
healthcare practice. Previously, he was Co-Head of Healthcare Investment
Banking at Piper Jaffray. Prior to that, Mr. Duty held senior-level positions
in healthcare investment banking at Montgomery Securities and Kidder Peabody &

Also from Piper Jaffray, Messrs. Gerber and Shin are joining Guggenheim
Securities as Managing Director and Vice President, respectively. Together,
they have over 25 years experience advising specialty pharmaceutical and
biotechnology companies across a range of financing and M&A transactions.

"Ron, Barry and I are pleased to join the Guggenheim Securities team," added
Mr. Duty. "The firm's accomplishments in the healthcare sector, as well as the
steady growth of the entire investment banking franchise, are highly regarded
throughout the industry. We look forward to building on the success with new
mandates and advisory relationships."

Since its launch in 2009, Guggenheim Securities' healthcare investment banking
and advisory practice has advised Pfizer on its $2.4 billion sale of Capsugel
to KKR and Merck KGaA on its $7 billion acquisition of Millipore, in addition
to numerous mid-market transactions. Guggenheim Securities is also building a
healthcare-focused sales and trading team, and the firm publishes healthcare
market commentary focused on regulatory and legislative issues through its
Washington Research Group.

About Guggenheim Partners
Guggenheim Partners, LLC is a privately held global financial services firm
with more than $160 billion in assets under management. The firm provides
asset management, investment banking and capital markets services, insurance,
institutional finance and investment advisory solutions to institutions,
governments and agencies, corporations, investment advisors, family offices
and individuals. Guggenheim Partners is headquartered in New York and Chicago
and serves clients around the world from more than 25 offices innine
countries. For more information about Guggenheim Partners, visit


Guggenheim Partners
Torie von Alt


Brunswick Group
Tripp Kyle / Felipe Ucros / Liz Bruce

SOURCE Guggenheim Partners, LLC

Press spacebar to pause and continue. Press esc to stop.